Vanguard Global Advisers
ANIP icon

Vanguard Global Advisers’s ANI Pharmaceuticals ANIP Stock Holding History

Vanguard Global Advisers’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$547K Sell
6,603
-521
-7% -$41.8K ﹤0.01% 2058
2026
Q1 		$548K Buy
+7,124
New +$556K ﹤0.01% 1994

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's ANIP Position: Q2 2026 in Review

Vanguard Global Advisers reduced its ANI Pharmaceuticals (ANIP) stake by 7.3% in Q2 2026, selling an estimated $41.8K and leaving 6,603 shares worth $547K. The position accounts for ﹤0.01% of the portfolio, ranked #2058.

Vanguard Global Advisers first reported a position in ANIP in Q1 2026 and has held it in 2 quarters since. The position peaked at $548K in Q1 2026. 306 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Vanguard Global Advisers held 6,603 shares of ANI Pharmaceuticals worth $547K as of Q2 2026.
  • Vanguard Global Advisers sold 521 ANI Pharmaceuticals shares in Q2 2026, an estimated $41.8K.
  • ANI Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2058 holding.
  • Vanguard Global Advisers first reported a position in ANI Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's ANI Pharmaceuticals position peaked at $548K in Q1 2026.
  • 306 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.